Aether Biomachines, the company reindustrializing America by turning AI-designed proteins into real-world solutions, today announced Jay Zaveri, Founder and Partner at Natural Capital, as president.
In this capacity, Zaveri will lead growth and bring Aether’s AI-designed proteins to market at scale.
“Jay has been a trusted adviser of Aether for several years, and I’ve seen him as a cofounder in this journey. As president, he will lean into his entrepreneurial expertise to lead growth,” said Pavle Jeremić, CEO and Founder of Aether Biomachines. “Our AI-designed proteins are already delivering results across materials and industrial applications, and Jay’s addition to the leadership team will allow us to strategically scale our operations.”
“By combining AI and robotics with chemistry, Aether can tackle problems that were once considered too complex or costly,” Zaveri said. “Our process for developing new proteins will bring the future of manufacturing and sustainability into the present, reducing chemical factories to the size of shipping containers.”
Zaveri brings decades of entrepreneurial and investment experience to Aether, where he has served on the board of directors since 2022. He has co-founded three tech companies, including CloudOn, which reached 10 million enterprise users and was acquired by Dropbox, and has spent nearly a decade managing $1.1 billion in early-stage venture capital funds that generated $4.5 billion in value.
His addition as president comes on the heels of Aether’s $15 million funding round, led by Tribe Capital, with participation from new and existing investors including Natural Capital, Henkel, Resilience Reserve, Shrug Capital, 4DX Ventures, Unless, and Radicle Impact.
To learn more about Aether, visit: https://www.aetherbio.com
About Aether Biomachines
Aether Biomachines is an American artificial intelligence company that discovers proteins with high-impact, real-world applications. At the core of its work is a Protein Function Model that can unlock new proteins for novel functions. Aether’s AI is being built on an entirely proprietary dataset developed in-house through advanced high-throughput screening and innovative assay technology. Using this platform, Aether has developed seven new classes of proteins with capabilities ranging from refining metals at lower cost and breaking down persistent “forever chemicals” to producing industry-leading materials, enabling complex pharmaceutical manufacturing, recycling plastics, and capturing carbon dioxide. Aether is already translating its AI breakthroughs into practice, commercializing high-performance materials that can print ten times faster than current industry benchmarks while offering superior strength for the defense and aerospace industries. Learn more at https://www.aetherbio.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251204790451/en/
Contacts
Media Contact
Michelle Mead
VSC for Aether Biomachines
aetherbio@vsc.co